Pricing Log in Create free account

iBio, Inc. (IBIO) vs INmune Bio, Inc. (INMB)

iBio, Inc. and INmune Bio, Inc. are both Biotechnology companies. iBio, Inc. and INmune Bio, Inc. are of similar size ($47.6M and $45.8M). INmune Bio, Inc. grew revenue faster over the last twelve months: −51.6% against −66.6%. Across the 13 metrics below, iBio, Inc. leads on 9 and INmune Bio, Inc. on 4.

Valuation

Metric IBIO INMB Biotechnology median
P/E n/m n/m 8.50
P/S 118.71 310.73 9.71
P/B 0.93 2.06 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.19 n/m 0.64
EV/Sales (9.70) 210.43 9.21
Earnings yield (44.16%) (42.68%) (33.15%)
Free cash flow yield (30.24%) (39.17%) (25.50%)

Profitability

Metric IBIO INMB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (65.70%) (74.82%) (56.36%)
Return on assets (54.04%) (57.08%) (48.04%)
Return on invested capital 0.00% (646.94%) 0.00%

Growth

Metric IBIO INMB Biotechnology median
Revenue growth (TTM) (66.55%) (51.61%) 6.02%
EPS growth (last fiscal year) 81.71% 11.85% 30.26%
Revenue growth, 5-year CAGR (42.83%) 35.37% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IBIO INMB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.85 4.04 4.72
Net debt to EBITDA 2.57 0.52 0.96

Dividend

Metric IBIO INMB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IBIO INMB Biotechnology median
Market cap 47.63m 45.80m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack